Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients

Charlotte D.C.C. van der Heijden, Rob ter Heine, Emma J. Kooistra, Roger J. Brüggemann, Jesper W.J. Walburgh Schmidt, Elke P.L.M. de Grouw, Tim Frenzel, Peter Pickkers, Jenneke Leentjens

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

3 Citaten (Scopus)


Critically ill COVID-19 patients are at high risk of thromboembolic events despite routine-dosed low-molecular-weight heparin thromboprophylaxis. However, in recent randomized trials increased-intensity thromboprophylaxis seemed futile and possibly even harmful. In this explorative pharmacokinetic (PK) study we measured anti-Xa activities on frequent timepoints in 15 critically ill COVID-19 patients receiving dalteparin and performed PK analysis by nonlinear mixed-effect modelling. A linear one-compartment model with first-order kinetics provided a good fit. However, wide interindividual variation in dalteparin absorption (variance 78%) and clearance (variance 34%) was observed, unexplained by routine clinical covariates. Using the final PK model for Monte Carlo simulations, we predicted increased-intensity dalteparin to result in anti-Xa activities well over prophylactic targets (0.2-0.4 IU/mL) in the majority of patients. Therapeutic-intensity dalteparin results in supratherapeutic anti-Xa levels (target 0.6-1.0 IU/mL) in 19% of patients and subtherapeutic levels in 22%. Therefore, anti-Xa measurements should guide high-intensity dalteparin in critically ill COVID-19 patients.

Originele taal-2Engels
Pagina's (van-tot)2982-2987
Aantal pagina's6
TijdschriftBritish Journal of Clinical Pharmacology
Nummer van het tijdschrift6
StatusGepubliceerd - jun. 2022
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Effects of dalteparin on anti-Xa activities cannot be predicted in critically ill COVID-19 patients'. Samen vormen ze een unieke vingerafdruk.

Citeer dit